These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1669260)

  • 1. [Thymidine kinase as a biological marker in neoplasms of the lung and mediastinum].
    De Blasio F; Alonzo M; Zofra S; De Colle R; Romano L; Pezza A
    Arch Monaldi Mal Torace; 1990; 45(1):39-48. PubMed ID: 1669260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thymidine kinase: a serum marker in clinical medicine].
    Llobell Segui GJ; Blasco Ferrandiz RF; Barbero Marín A; Gómez de Terreros FJ; Callol Sánchez L
    An Med Interna; 1989 Jul; 6(7):381-5. PubMed ID: 2562370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
    Schneider J; Morr H; Velcovsky HG; Weisse G; Eigenbrodt E
    Cancer Detect Prev; 2000; 24(6):531-5. PubMed ID: 11198266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic usefulness of the determination of serum neuron-specific enolase in small cell bronchial carcinoma].
    Romero S; Padilla I; Mauri M; García-Sevila R; Martín C; Pérez-Carbonell A
    Med Clin (Barc); 1990 Jun; 95(1):10-4. PubMed ID: 2172670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mediastinoscopy: a superior alternative to exploratory thoracotomy?
    Anas P; Chavez CM; Ratliff J; Conn JH
    J Miss State Med Assoc; 1971 Oct; 12(10):523-8. PubMed ID: 5095304
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
    Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
    Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor markers in bronchus cancer].
    Gasser RW; Denz H; Huber H
    Wien Klin Wochenschr; 1989 Jul; 101(14):476-9. PubMed ID: 2549731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
    Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
    Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cut-off levels of NSE to differentiate SCLC from NSCLC.
    Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
    Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic significance of the tumor markers CEA, SCC and NSE in serum and bronchoalveolar lavage].
    von Eiff M; Koch O; Appelhans N; Roos N; van de Loo J
    Pneumologie; 1990 Feb; 44 Suppl 1():462-4. PubMed ID: 2164198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
    Bubanović G; Pavićević R; Franjević A
    Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood.
    Yamamoto O; Takahashi H; Hirasawa M; Chiba H; Shiratori M; Kuroki Y; Abe S
    Respir Med; 2005 Sep; 99(9):1164-74. PubMed ID: 16085219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
    Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
    Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
    Pavićević R; Milicić J; Bubanović G; Supe S
    Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
    Oremek GM; Sapoutzis N
    Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.